Post-marketing safety surveillance of pneumococcal vaccines: a real-world pharmacovigilance study using the U.S. vaccine adverse event reporting system (VAERS) database
This post-marketing surveillance has revealed predominantly non-serious AEs, with most adverse events clustered within 30 days post-vaccination. These observations reinforce the established safety profile of pneumococcal vaccines while emphasizing temporal risk patterns to guide post-vaccination monitoring protocols and risk-benefit evaluations.
Authors
- F.L. Kong (ORCID: https://orcid.org/0000-0002-2589-5619)
- Yandong Peng (ORCID: https://orcid.org/0000-0002-5376-0308)
- Xin Zheng (ORCID: https://orcid.org/0000-0001-9176-8856)
- Ling Juan Wu (ORCID: https://orcid.org/0000-0003-2432-8820)
- Xi Yang (ORCID: https://orcid.org/0000-0002-5691-1888)
- Shihong Zhang (ORCID: https://orcid.org/0000-0002-0905-6292)
- Aili Ding
- Weijia Sun (ORCID: https://orcid.org/0000-0003-3604-6919)
- M Liu (ORCID: https://orcid.org/0009-0007-7667-5249)
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
- Dalian Municipal Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Cellular and Infection Microbiology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.3389/fcimb.2025.1635180
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Dalian University of Technology